Lecanemab and Donanemab Combination Therapy for Alzheimer's Disease-The Cocktail May Work Even Better Together - PubMed
6 hours ago
- #Alzheimer's disease
- #combination therapy
- #antiamyloid immunotherapy
- Lecanemab and Donanemab are FDA-approved antiamyloid immunotherapies for Alzheimer's disease.
- Lecanemab targets amyloid protofibrils, while Donanemab targets amyloid plaques intracranially.
- Combination therapy of both drugs may produce an augmented effect.
- Research on combination therapy requires collaboration between pharmaceutical companies, academia, government, and advocacy groups.